Mark C. Markowski

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

Sarina A. Piha‐Paul, Christine L. Hann, Christopher A. French et al. · JNCI Cancer Spectrum · 2019 · 196 citations · Full text

Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies

Karen S. Sfanos, Mark C. Markowski, Lauren B. Peiffer et al. · Prostate Cancer and Prostatic Diseases · 2018 · 141 citations · Full text

Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer

Pedro Isaacsson Velho, John L. Silberstein, Mark C. Markowski et al. · The Prostate · 2018 · 136 citations · Full text

TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer

Samuel R. Denmeade, Hao Wang, Neeraj Agarwal et al. · Journal of Clinical Oncology · 2021 · 133 citations · Full text

Androgen blocks apoptosis of hormone-dependent prostate cancer cells.

Kotohiko Kimura, Mark C. Markowski, Cai Bowen et al. · PubMed · 2001 · 97 citations

Urology, Oncology, Androgen Blocks Apoptosis +14